New data show Kyntheum achieves greater possibility of complete skin clearance

Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, France, show that treatment with Kyntheum (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab.

The possibility of attaining completely clear skin makes a significant difference to the lives of people with psoriasis, according to the newly published PsoClear Report, says the drug’s marketer, Danish dermatology specialist LEO Pharma, which received European approval for the drug in July 2017.

Kyntheum, the European rights to which were licensed to LEO Pharma in July 2016 by its developer AstraZeneca (LSE: AZN) for an upfront payment of $115 million with up to $1 billion in commercially-related milestones, is the first and only biologic that selectively targets the interleukin (IL)-17 receptor subunit A.